1 EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, made and entered into as of October 15, 1999 (the "EFFECTIVE DATE"), by and between Lexicon Genetics Incorporated, a Delaware corporation (hereafter "COMPANY"), and Arthur T. Sands, M.D.,...Employment Agreement • February 9th, 2000 • Lexicon Genetics Inc/Tx • Texas
1 EXHIBIT 10.12 PARTICIPATION AGREEMENT Dated as of October 19, 2000Participation Agreement • March 15th, 2001 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • North Carolina
EXHIBIT 1.1 10,000,000 SHARES LEXICON GENETICS INCORPORATED COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2003 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New York
Exhibit 99.3 FIRST AMENDMENT OF LEASE AGREEMENT THIS FIRST AMENDMENT OF LEASE AGREEMENT (hereinafter referred to as this "Amendment"), made as of the 16th day of January, 2003, by and between TOWNSEND PROPERTY TRUST LIMITED PARTNERSHIP, a limited...Lease Agreement • July 24th, 2003 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New Jersey
BY AND AMONGMerger Agreement • June 18th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
1 EXHIBIT 10.6 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT is made as of _________, _____, by and between LEXICON GENETICS INCORPORATED, a Delaware corporation (the "Company"), and ___________ ("Indemnitee"). WHEREAS, the Certificate of...Indemnification Agreement • February 9th, 2000 • Lexicon Genetics Inc/Tx • Delaware
1 EXHIBIT 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, made and entered into as of January 1, 1999 (the "EFFECTIVE DATE"), by and between Lexicon Genetics Incorporated, a Delaware corporation (hereafter "COMPANY"), and Jeffrey L. Wade...Employment Agreement • February 9th, 2000 • Lexicon Genetics Inc/Tx • Texas
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, made and entered into as of July 12, 2001 (this "AGREEMENT"), by and between Lexicon Genetics Incorporated, a Delaware corporation (hereafter "COMPANY"), and Hartmuth Kolb, Ph.D. (hereafter...Employment Agreement • November 14th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New Jersey
WITNESSETH:Registration Rights Agreement • August 10th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
19,894,076 Shares LEXICON PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • October 9th, 2009 • Lexicon Pharmaceuticals, Inc./De • Pharmaceutical preparations • New York
The undersigned understands that Morgan Stanley & Co. Incorporated (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley (the “Underwriters”), of shares (the “Shares”) of the common stock, par value $0.001 per share, of the Company (the “Common Stock”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • December 29th, 2023 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AGREEMENTConfidentiality Agreement • March 1st, 2000 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • New Jersey
LEASE AGREEMENTLease Agreement • March 1st, 2000 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • Texas
WITNESSETH:Employment Agreement • March 3rd, 2006 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Texas
LEXICON PHARMACEUTICALS, INC. 23,924,705 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • June 2nd, 2023 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EXHIBIT 10.1 [LEXICON GENETICS LETTERHEAD] February 19, 2003 Dr. Alan S. Nies Dear Alan: We are pleased to invite you to become the Chairman of the Medical Advisory Board of, and a special consultant to, Lexicon Genetics Incorporated (which, together...Consulting Agreement • April 30th, 2004 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Texas
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 5th, 2022 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations
This LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 17, 2022 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and OXFORD FINANCE CREDIT FUND III, LP, by its manager Oxford Finance Advisors, LLC (“Credit Fund”; each a “Lender” and collectively, the “Lenders”), LEXICON PHARMACEUTICALS, INC. (“Parent”) and LEXICON PHARMACEUTICALS (NEW JERSEY), INC. (“Lex-NJ”), each a Delaware corporation with offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, TX 77381 (Parent and Lex-NJ, individually and collectively, jointly and severally, “Borrower”), provides th
Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, made and entered into as of February 8, 2000 (the "EFFECTIVE DATE"), by and between Lexicon Genetics Incorporated, a Delaware corporation (hereafter "COMPANY"), and Julia Gregory (hereafter...Employment Agreement • March 1st, 2000 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • Texas
SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 3rd, 2006 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.1 March 31, 2003 VIA FEDERAL EXPRESS Dr. Robert J. Lefkowitz Duke University Medical Center Box 3821 Durham, North Carolina 27710 Dear Bob: We are delighted that you, an investigator of the Howard Hughes Medical Institute (the "Institute")...Consulting Agreement • May 9th, 2003 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Texas
AGREEMENTResearch and Development • April 6th, 2000 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • New Jersey
LEASELease Agreement • March 25th, 2002 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances
17,500,000 Shares LEXICON PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • October 19th, 2012 • Lexicon Pharmaceuticals, Inc./De • Pharmaceutical preparations • New York
The undersigned understands that J.P. Morgan Securities LLC (“J.P. Morgan”) and Jefferies & Company, Inc. (“Jefferies”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including J.P. Morgan and Jefferies (the “Underwriters”), of shares (the “Shares”) of the common stock, par value $0.001 per share, of the Company (the “Common Stock”).
EXHIBIT 10.1 [LEXICON GENETICS LETTERHEAD] March 28, 2005 VIA FEDERAL EXPRESS Dr. C. Thomas Caskey Five Post Oak Park 4400 Post Oak Parkway, Suite 1400 Houston, Texas 77027 Dear Tom: We are pleased to invite you to become a consultant to Lexicon...Consulting Agreement • April 1st, 2005 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Texas
BY AND BETWEENCollaboration Agreement • November 2nd, 2004 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New York
RECITALSCollaboration and License Agreement • July 16th, 2004 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
1 2 necessary or desirable for carrying out the functions of the Representative thereunder and otherwise administering the indemnification and escrow distribution provisions set forth in Article 8 of the Merger Agreement. The Stockholder agrees that...Stockholder Agreement • August 10th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
RECITALSDatabase Access Agreement • March 1st, 2000 • Lexicon Genetics Inc/Tx • Services-commercial physical & biological research • Delaware
REAL ESTATE PURCHASE AND SALE AGREEMENT BETWEEN LEX-GEN WOODLANDS, L.P. AND Nurix Therapeutics, Inc. CONCERNING PROPERTY COMMONLY KNOWN AS 8800 TECHNOLOGY FOREST PLACE IN THE WOODLANDS, TEXASReal Estate Purchase and Sale Agreement • October 22nd, 2020 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Texas
This instrument was acknowledged before me on ___________, 20__, by _____________________, __________________________ of Lex-Gen Woodlands GP, LLC, a Delaware limited liability company, sole general partner of Lex-Gen Woodlands, L.P., a Delaware limited partnership, on behalf of said limited partnership.
RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • March 25th, 2024 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Unit Agreement (this “Agreement”), effective as of ____________ (the “Grant Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and _____________ (“Employee”).
EXHIBIT 10.18 LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 14th, 2005 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • New York
EXHIBIT 10.17 STOCK OPTION AGREEMENT (CHAIRMAN OF BOARD OF DIRECTORS STOCK OPTION) THIS STOCK OPTION AGREEMENT (this "Agreement"), effective as of ______________ (the "Grant Date"), is by and between LEXICON GENETICS INCORPORATED, a Delaware...Stock Option Agreement • March 3rd, 2006 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
STOCK OPTION AGREEMENT (Officer Incentive Stock Option)Stock Option Agreement • March 1st, 2018 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK OPTION AGREEMENT (this “Agreement”), effective as of __________ (the “Grant Date”), is by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and _____________ (“Optionee”).
20,312,500 SHARES OF COMMON STOCK PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 11th, 2020 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this Placement Agency Agreement (the “Agreement”) and the Purchase Agreements (as defined in Section 1(a) hereof), to sell to certain investors (each, an “Investor” and collectively, the “Investors”) an aggregate of 20,312,500 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), in an offering under the Company’s registration statement on Form S-3 (Registration No. 333-234568).
PREFERRED STOCK PURCHASE AGREEMENT dated as of March 11, 2024 by and among LEXICON PHARMACEUTICALS, INC. and THE PURCHASERS PARTY HERETOPreferred Stock Purchase Agreement • March 11th, 2024 • Lexicon Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of March 11, 2024 (the “Execution Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”). Capitalized terms used but not defined have the meanings ascribed to them in Section 5.9 of this Agreement.
